Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verastem (VSTM) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Verastem (VSTM) over the last 8 years, with Sep 2025 value amounting to $137.7 million.

  • Verastem's Cash & Equivalents rose 21.68% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 21.68%. This contributed to the annual value of $88.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Verastem reported Cash & Equivalents of $137.7 million as of Q3 2025, which was down 16.20% from $164.3 million recorded in Q2 2025.
  • Verastem's Cash & Equivalents' 5-year high stood at $183.1 million during Q2 2023, with a 5-year trough of $24.3 million in Q3 2021.
  • Over the past 3 years, Verastem's median Cash & Equivalents value was $105.2 million (recorded in 2023), while the average stood at $116.2 million.
  • As far as peak fluctuations go, Verastem's Cash & Equivalents tumbled by 85.74% in 2021, and later skyrocketed by 221.49% in 2022.
  • Over the past 5 years, Verastem's Cash & Equivalents (Quarterly) stood at $74.8 million in 2021, then grew by 5.73% to $79.1 million in 2022, then increased by 21.52% to $95.0 million in 2023, then increased by 19.15% to $88.8 million in 2024, then increased by 21.68% to $137.7 million in 2025.
  • Its Cash & Equivalents was $137.7 million in Q3 2025, compared to $164.3 million in Q2 2025 and $117.6 million in Q1 2025.